Tmunity Therapeutics raises $10M

Tmunity Therapeutics, a new Philadelphia company co-founded by immunotherapy pioneer Dr. Carl June of the University of Pennsylvania’s Perelman School of Medicine, raised $10 million in an equity financing from Penn Medicine and venture capital firm Lilly Asia Ventures.

Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors.

Share this post